Abstract :

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a kind of inflammatory neuropathy that has a gradual start and symmetrical sensory involvement. However, there are several clinical variances, suggesting that CIDP may represent a spectrum of linked disorders rather than a single disease entity. While the prevailing idea of CIDP pathogenesis is that cell-mediated and humoral processes interact in an abnormal immune response to damage peripheral neurons, the proportional roles of T cell and autoantibody responses are yet unknown. T cell responses to specified myelin antigens are responsible in animal models of spontaneous inflammatory neuropathy. Antibodies to Schwann cell, compact myelin, and nodal antigens have been found in different human inflammatory neuropathies. The roles of the cellular and humoral immune systems in the development of CIDP are discussed in this review. It is believed that, in the future, the identification of clinical phenotypes and the underlying disease processes would aid in the development of diagnostic and therapy options for CIDP.

---

Keywords :

Myelin, Neuroimmunology, Neuropathy, Neurophysiology, Schwann cell

---

References :

1. McLeod JG, Pollard JD, Macaskill P, et al. . Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol1999;46:910–13. 10.1002/1531-8249(199912)46:6<910::AID-ANA14>3.0.CO;2-2.
2. Chio A, Cocito D, Bottacchi E, et al. . Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy. J NeurolNeurosurg Psychiatry2007;78:1349–53. 10.1136/jnnp.2007.114868.
3. Iijima M, Koike H, Hattori N, et al. . Prevalence and incidence rates of chronic inflammatory demyelinating polyneuropathy in the Japanese population. J NeurolNeurosurg Psychiatry2008;79:1040–3. 10.1136/jnnp.2007.128132.
4. Lunn MP, Manji H, Choudhary PP, et al. . Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J NeurolNeurosurg Psychiatry1999;66:677–80. 10.1136/jnnp.66.5.677.
5. Mahdi-Rogers M, Hughes RA. Epidemiology of chronic inflammatory neuropathies in southeast England. Eur J Neurol2014;21:28–33. 10.1111/ene.12190.
6. Rajabally YA, Simpson BS, Beri S, et al. . Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve2009;39:432–8. 10.1002/mus.21206.
7. Van den Bergh PY, Hadden RD, Bouche P, et al. . European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. Eur J Neurol2010;17:356–63. 10.1111/j.1468-1331.2009.02930.x.
8. Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. J Neurol2003;250:714–24. 10.1007/s00415-003-1068-2.
9. Viala K, Maisonobe T, Stojkovic T, et al. . A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J PeripherNervSyst2010;15:50–6. 10.1111/j.1529-8027.2010.00251.x.
10. Rotta FT, Sussman AT, Bradley WG, et al. . The spectrum of chronic inflammatory demyelinating polyneuropathy. J NeurolSci2000;173:129–39. 10.1016/S0022-510X(99)00317-2.
11. Ayrignac X, Viala K, Koutlidis RM, et al. . Sensory chronic inflammatory demyelinating polyneuropathy: an under-recognized entity?Muscle Nerve 2013;48:727–32. 10.1002/mus.23821.
12. Ohkoshi N, Harada K, Nagata H, et al. . Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy: clinical features and pathological study of the sural nerves. EurNeurol2001;45:241–8. 10.1159/000052136.
13. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology1997;48:321–8. 10.1212/WNL.48.2.321.
14. Lewis RA, Sumner AJ, Brown MJ, et al. . Multifocal demyelinating neuropathy with persistent conduction block. Neurology1982;32:958–64. 10.1212/WNL.32.9.958.
15. Thomas PK, Claus D, Jaspert A, et al. . Focal upper limb demyelinating neuropathy. Brain1996;119(Pt 3):765–74. 10.1093/brain/119.3.765.
16. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases. Brain1987;110(Pt 6):1617–30. 10.1093/brain/110.6.1617.
17. Ruts L, Drenthen J, Jacobs BC, et al. . Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology2010;74:1680–6. 10.1212/WNL.0b013e3181e07d14.
18. Odaka M, Yuki N, Hirata K. Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome. J Neurol2003;250:913–16. 10.1007/s00415-003-1096-y.
19. Said G, Krarup C. Chronic inflammatory demyelinative polyneuropathy. HandbClinNeurol2013;115:403–13. 10.1016/B978-0-444-52902-2.00022-9.
20. Nobile-Orazio E. Chronic inflammatory demyelinating polyradiculoneuropathy and variants: where we are and where we should go. J PeripherNervSyst2014;19:2–13. 10.1111/jns5.12053.
21. Oh SJ, Joy JL, Kuruoglu R. “Chronic sensory demyelinating neuropathy”: chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J NeurolNeurosurg Psychiatry1992;55:677–80. 10.1136/jnnp.55.8.677.
22. Rajabally YA, Wong SL. Chronic inflammatory pure sensory polyradiculoneuropathy: a rare CIDP variant with unusual electrophysiology. J ClinNeuromuscul Dis2012;13:149–52. 10.1097/CND.0b013e31822484fb.
23. vanDijk GW, Notermans NC, Franssen H, et al. . Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation: a long-term follow-up study. J Neurol1999;246:1134–9. 10.1007/s004150050531.
24. Sinnreich M, Klein CJ, Daube JR, et al. . Chronic immune sensory polyradiculopathy: a possibly treatable sensory ataxia. Neurology2004;63:1662–9. 10.1212/01.WNL.0000142507.12763.58.
25. Yiannikas C, Vucic S. Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy. Muscle Nerve2008;38:1447–54. 10.1002/mus.21078.
26. Katz JS, Saperstein DS, Gronseth G, et al. . Distal acquired demyelinating symmetric neuropathy. Neurology2000;54:615–20. 10.1212/WNL.54.3.615.
27. Saperstein DS, Katz JS, Amato AA, et al. . Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve2001;24:311–24. 10.1002/1097-4598(200103)24:3<311::AID-MUS1001>3.0.CO;2-A.
28. Larue S, Bombelli F, Viala K, et al. . Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol2011;18:899–905. 10.1111/j.1468-1331.2010.03312.x.
29. Sabatelli M, Madia F, Mignogna T, et al. . Pure motor chronic inflammatory demyelinating polyneuropathy. J Neurol2001;248:772–7. 10.1007/s004150170093.
30. Kimura A, Sakurai T, Koumura A, et al. . Motor-dominant chronic inflammatory demyelinating polyneuropathy. J Neurol2010;257:621–9. 10.1007/s00415-009-5386-x.
31. Hattori N, Misu K, Koike H, et al. . Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy. J NeurolSci2001;184:57–63. 10.1016/S0022-510X(00)00493-7.
32. Rajabally YA, Chavada G. Lewis-sumner syndrome of pure upper-limb onset: diagnostic, prognostic, and therapeutic features. Muscle Nerve2009;39:206–20. 10.1002/mus.21199.
33. Saperstein DS, Amato AA, Wolfe GI, et al. . Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve1999;22:560–6. 10.1002/(SICI)1097-4598(199905)22:5<560::AID-MUS2>3.0.CO;2-Q.
34. Viala K, Renie L, Maisonobe T, et al. . Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome. Brain2004;127:2010–17. 10.1093/brain/awh222.
35. Verma A, Tandan R, Adesina AM, et al. . Focal neuropathy preceding chronic inflammatory demyelinating polyradiculoneuropathy by several years. ActaNeurolScand1990;81:516–21. 10.1111/j.1600-0404.1990.tb01011.x.
36. Ayrignac X, Rodrigues BS, Morales R, et al. . Focal CIDP presenting as chronic progressive monomelic sensory neuropathy. Muscle Nerve2013;47: 143–4. 10.1002/mus.23541.
37. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol1990;27(Suppl):S21–4. 10.1002/ana.410270707.
38. Sung JY, Tani J, Park SB, et al. . Early identification of ‘acute-onset’ chronic inflammatory demyelinating polyneuropathy. Brain2014;137:2155–63. 10.1093/brain/awu158.
39. Hughes R, Sanders E, Hall S, et al. . Subacute idiopathic demyelinating polyradiculoneuropathy. Arch Neurol1992;49:612–16. 10.1001/archneur.1992.00530300044009.
40. Oh SJ, Kurokawa K, de Almeida DF, et al. . Subacute inflammatory demyelinating polyneuropathy. Neurology2003;61:1507–12. 10.1212/01.WNL.0000096166.28131.4C.
41. Rodriguez-Casero MV, Shield LK, Kornberg AJ. Subacute inflammatory demyelinating polyneuropathy in children. Neurology2005;64:1786–8. 10.1212/01.WNL.0000162047.89440.B9.
42. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J PeripherNervSyst2010;15:185–95. 10.1111/j.1529-8027.2010.00278.x.
43. Niermeijer JM, Fischer K, Eurelings M, et al. . Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurology2010;74:406–12. 10.1212/WNL.0b013e3181ccc6b9.
44. Nobile-Orazio E, Manfredini E, Carpo M, et al. . Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol1994;36:416–24. 10.1002/ana.410360313.
45. Nobile-Orazio E, Meucci N, Baldini L, et al. . Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain2000;123(Pt 4):710–17. 10.1093/brain/123.4.710.
46. Rajabally YA. Neuropathy and paraproteins: review of a complex association. Eur J Neurol2011;18:1291–8. 10.1111/j.1468-1331.2011.03380.x.
47. Kaku DA, England JD, Sumner AJ. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphatedglucuronylparagloboside. Brain1994;117(Pt 5):941–7. 10.1093/brain/117.5.941.
48. Suarez GA, Kelly JJ Jr. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology1993;43:1304–8. 10.1212/WNL.43.7.1304.
49. Magy L, Chassande B, Maisonobe T, et al. . Polyneuropathy associated with IgG/IgA monoclonal gammopathy: a clinical and electrophysiological study of 15 cases. Eur J Neurol2003;10:677–85. 10.1046/j.1468-1331.2003.00687.x.
50. Willison HJ, O’Leary CP, Veitch J, et al. . The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosylIgM antibodies. Brain2001;124:1968–77. 10.1093/brain/124.10.1968.
51. Nobile-Orazio E, Gallia F, Terenghi F, et al. . How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies?J NeurolSci 2008;266:156–63. 10.1016/j.jns.2007.09.020.
52. Kam C, Balaratnam MS, Purves A, et al. . Canomad presenting without ophthalmoplegia and responding to intravenous immunoglobulin. Muscle Nerve2011;44:829–33. 10.1002/mus.22167.
53. Nasu S, Misawa S, Sekiguchi Y, et al. . Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy. J NeurolNeurosurg Psychiatry2012;83:476–9. 10.1136/jnnp-2011-301706.
54. Nobile-Orazio E. Neuropathy and monoclonal gammopathy. In: Said G, Krarup C. Handbook of clinical neurology. Amsterdam: Elsevier, 2013:443–59.
55. Watanabe O, Maruyama I, Arimura K, et al. . Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve1998;21:1390–7. 10.1002/(SICI)1097-4598(199811)21:11<1390::AID-MUS5>3.0.CO;2-4.
56. Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—first revision. J PeripherNervSyst2010;15:295–301. 10.1111/j.1529-8027.2010.00290.x.
57. Arcila-Londono X, Lewis RA. Multifocal Motor Neuropathy. In: Said G, Krarup C. Handbook of clinical neurology. Amsterdam: Elsevier, 2013:429–42.
58. Taylor BV, Dyck PJ, Engelstad J, et al. . Multifocal motor neuropathy: pathologic alterations at the site of conduction block. J NeuropatholExpNeurol2004;63:129–37.
59. Taylor BV, Wright RA, Harper CM, et al. . Natural history of 46 patients with multifocal motor neuropathy with conduction block. Muscle Nerve2000;23:900–8. 10.1002/(SICI)1097-4598(200006)23:6<900::AID-MUS9>3.0.CO;2-Y.
60. Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates. Neurology1997;49:1289–92. 10.1212/WNL.49.5.1289.
61. vanSchaik IN, Bossuyt PM, Brand A, et al. . Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis. Neurology1995;45:1570–7. 10.1212/WNL.45.8.1570.
62. Cats EA, Jacobs BC, Yuki N, et al. . Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology2010;75:1961–7. 10.1212/WNL.0b013e3181ff94c2.
63. Galban-Horcajo F, Fitzpatrick AM, Hutton AJ, et al. . Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurol2013;20:62–70. 10.1111/j.1468-1331.2012.03767.x.
64. Nobile-Orazio E, Cappellari A, Priori A. Multifocal motor neuropathy: current concepts and controversies. Muscle Nerve2005;31:663–80. 10.1002/mus.20296.
65. Willison HJ, Veitch J, Swan AV, et al. . Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol1999;6:71–7. 10.1046/j.1468-1331.1999.610071.x.
66. Donaghy M, Mills KR, Boniface SJ, et al. . Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J NeurolNeurosurg Psychiatry1994;57:778–83. 10.1136/jnnp.57.7.778.
67. Breiner A, Brannagan TH III. Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle Nerve2014;50:40–6. 10.1002/mus.24088.
68. Rajabally YA, Fowle AJ, Van den Bergh PY. Which criteria for research in CIDP? An analysis of current practice. Muscle Nerve 10.1002/mus.24496 (In press).
69. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J NeurolSci1976;27:427–58. 10.1016/0022-510X(76)90213-6.
70. Sommer C, Koch S, Lammens M, et al. . Macrophage clustering as a diagnostic marker in sural nerve biopsies of patients with CIDP. Neurology2005;65:1924–9. 10.1212/01.wnl.0000188879.19900.b7.
71. Bosboom WM, van den Berg LH, De BL, et al. . The diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy. Neurology1999;53:837–45. 10.1212/WNL.53.4.837.
72. Pollard JD, McCombe PA, Baverstock J, et al. . Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol1986;13:123–34. 10.1016/0165-5728(86)90059-7.
73. Schmidt B, Toyka KV, Kiefer R, et al. . Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve1996;19:474–87. 10.1002/(SICI)1097-4598(199604)19:4<474::AID-MUS8>3.0.CO;2-9.
74. Chi LJ, Xu WH, Zhang ZW, et al. . Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. J PeripherNervSyst2010;15:345–56. 10.1111/j.1529-8027.2010.00294.x.
75. Madia F, Frisullo G, Nociti V, et al. . pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. J PeripherNervSyst2009;14:107–17. 10.1111/j.1529-8027.2009.00220.x.
76. Hartung HP, Reiners K, Schmidt B, et al. . Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol1991;30:48–53. 10.1002/ana.410300110.
77. Rentzos M, Angeli AV, Rombos A, et al. . Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients. Neurol Res2012;34:842–6. 10.1179/1743132812Y.0000000074.
78. Gironi M, Saresella M, Marventano I, et al. . Distinct cytokine patterns associated with different forms of chronic dysimmune neuropathy. Muscle Nerve2010;42:864–70. 10.1002/mus.21786.
79. Sainaghi PP, Collimedaglia L, Alciato F, et al. . The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine2010;51:138–43. 10.1016/j.cyto.2010.05.005.
80. Misawa S, Kuwabara S, Mori M, et al. . Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology2001;56:666–9. 10.1212/WNL.56.5.666.
81. Press R, Pashenkov M, Jin JP, et al. . Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J ClinImmunol2003;23:259–67. 10.1023/A:1024532715775.
82. Kieseier BC, Tani M, Mahad D, et al. . Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain2002;125:823–34. 10.1093/brain/awf070.
83. Linington C, Lassmann H, Ozawa K, et al. . Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by P0 protein-specific T cell lines. Eur J Immunol1992;22:1813–17. 10.1002/eji.1830220721.
84. Pollard JD, Westland KW, Harvey GK, et al. . Activated T cells of nonneural specificity open the blood-nerve barrier to circulating antibody. Ann Neurol1995;37:467–75. 10.1002/ana.410370409.
85. Spies JM, Westland KW, Bonner JG, et al. . Intraneural activated T cells cause focal breakdown of the blood-nerve barrier. Brain1995;118(Pt 4):857–68. 10.1093/brain/118.4.857.
86. Spies JM, Pollard JD, Bonner JG, et al. . Synergy between antibody and P2-reactive T cells in experimental allergic neuritis. J Neuroimmunol1995;57:77–84. 10.1016/0165-5728(94)00164-J.
87. van den Berg LH, Mollee I, Wokke JH, et al. . Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol1995;58:37–42. 10.1016/0165-5728(94)00185-Q.
88. Mei FJ, Ishizu T, Murai H, et al. . Th1 shift in CIDP versus Th2 shift in vasculitic neuropathy in CSF. J NeurolSci2005;228:75–85. 10.1016/j.jns.2004.10.001.
89. Archelos JJ, Previtali SC, Hartung HP. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci1999;22:30–8. 10.1016/S0166-2236(98)01287-9.
90. Oka N, Akiguchi I, Nagao M, et al. . Expression of endothelial leukocyte adhesion molecule-1 (ELAM-1) in chronic inflammatory demyelinating polyneuropathy. Neurology1994;44:946–50. 10.1212/WNL.44.5.946.
91. Musso AM, Zanusso GL, Bonazzi ML, et al. . Increased serum levels of ICAM-1, ELAM-1 and TNF-alpha in inflammatory disorders of the peripheral nervous system. Ital J NeurolSci1994;15:267–71. 10.1007/BF02339236.
92. Leppert D, Hughes P, Huber S, et al. . Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemicvasculitic neuropathy. Neurology1999;53:62–70. 10.1212/WNL.53.1.62.
93. Kuwabara S, Nakajima M, Matsuda S, et al. . Magnetic resonance imaging at the demyelinative foci in chronic inflammatory demyelinatingpolyneuropathy. Neurology1997;48:874–7. 10.1212/WNL.48.4.874.
94. Schneider-Hohendorf T, Schwab N, Uceyler N, et al. . CD8+ T-cell immunity in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology2012;78:402–8. 10.1212/WNL.0b013e318245d250.
95. Cornblath DR, Griffin DE, Welch D, et al. . Quantitative analysis of endoneurial T-cells in human sural nerve biopsies. J Neuroimmunol1990;26:113–18. 10.1016/0165-5728(90)90082-X.
96. Kiefer R, Dangond F, Mueller M, et al. . Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies. J NeurolNeurosurg Psychiatry2000;69:362–8. 10.1136/jnnp.69.3.362.
97. Murata K, Dalakas MC. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain2000;123(Pt 8):1660–6. 10.1093/brain/123.8.1660.
98. Mathey EK, Pollard JD, Armati PJ. TNF alpha, IFN gamma and IL-2 mRNA expression in CIDP sural nerve biopsies. J NeurolSci1999;163:47–52. 10.1016/S0022-510X(99)00009-X.
99. Kiefer R, Kieseier BC, Stoll G, et al. . The role of macrophages in immune-mediated damage to the peripheral nervous system. ProgNeurobiol2001;64:109–27. 10.1016/S0301-0082(00)00060-5.
100. Vital C, Vital A, Lagueny A, et al. . Chronic inflammatory demyelinating polyneuropathy: immunopathological and ultrastructural study of peripheral nerve biopsy in 42 cases. UltrastructPathol2000;24:363–9. 10.1080/019131200750060023.
101. Steinhoff U, Kaufmann SH. Specific lysis by CD8+ T cells of Schwann cells expressing Mycobacterium leprae antigens. Eur J Immunol1988;18:969–72. 10.1002/eji.1830180622.
102. Mausberg AK, Dorok M, Stettner M, et al. . Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology2013;80:296–303. 10.1212/WNL.0b013e31827debad.
103. Sanvito L, Makowska A, Gregson N, et al. . Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity2009;42:667–77. 10.3109/08916930903140907.
104. Chi LJ, Wang HB, Wang WZ. Impairment of circulating CD4+CD25+ regulatory T cells in patients with chronic inflammatory demyelinating polyradiculoneuropathy. J PeripherNervSyst2008;13:54–63. 10.1111/j.1529-8027.2008.00158.x.
105. Salomon B, Rhee L, Bour-Jordan H, et al. . Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice. J Exp Med2001;194:677–84. 10.1084/jem.194.5.677.
106. Louvet C, Kabre BG, Davini DW, et al. . A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy. J Exp Med2009;206:507–14. 10.1084/jem.20082113.
107. Su MA, Davini D, Cheng P, et al. . Defective autoimmune regulator-dependent central tolerance to myelin protein zero is linked to autoimmune peripheral neuropathy. J Immunol2012;188:4906–12. 10.4049/jimmunol.1200493.
108. Meyer zu HG, Mausberg AK, Cordes S, et al. . Thymic epithelium determines a spontaneous chronic neuritis in Icam1tm1JcgrNOD Mice. J Immunol2014;193:2678–90. 10.4049/jimmunol.1400367.
109. Dalakas MC, Engel WK. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol1980;37:637–40. 10.1001/archneur.1980.00500590061010.
110. Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol1988;18:231–44. 10.1016/0165-5728(88)90101-4.
111. Yan WX, Taylor J, Ndrias-Kauba S, et al. . Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol2000;47:765–75. 10.1002/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8.
112. Heininger K, Liebert UG, Toyka KV, et al. . Chronic inflammatory polyneuropathy. Reduction of nerve conduction velocities in monkeys by systemic passive transfer of immunoglobulin G. J NeurolSci1984;66:1–14. 10.1016/0022-510X(84)90136-9.
113. Yan WX, Archelos JJ, Hartung HP, et al. . P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol2001;50:286–92. 10.1002/ana.1129.
114. Allen D, Giannopoulos K, Gray I, et al. . Antibodies to peripheral nerve myelin proteins in chronic inflammatory demyelinating polyradiculoneuropathy. J PeripherNervSyst2005;10:174–80. 10.1111/j.1085-9489.2005.0010207.x.
115. Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J NeurolNeurosurg Psychiatry2007;78:419–22. 10.1136/jnnp.2006.106617.
116. Khalili-Shirazi A, Atkinson P, Gregson N, et al. . Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol1993;46:245–51. 10.1016/0165-5728(93)90255-W.
117. Sanvito L, Makowska A, Mahdi-Rogers M, et al. . Humoral and cellular immune responses to myelin protein peptides in chronic inflammatory demyelinating polyradiculoneuropathy. J NeurolNeurosurg Psychiatry2009;80:333–8. 10.1136/jnnp.2008.159798.
118. Quarles RH, Ilyas AA, Willison HJ. Antibodies to gangliosides and myelin proteins in Guillain-Barré syndrome. Ann Neurol1990;27(Suppl):S48–52. 10.1002/ana.410270713.
119. Kwa MS, van Schaik IN, Brand A, et al. . Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J Neuroimmunol2001;116:220–5. 10.1016/S0165-5728(01)00307-1.
120. Melendez-Vasquez C, Redford J, Choudhary PP, et al. . Immunological investigation of chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol1997;73:124–34. 10.1016/S0165-5728(96)00189-0.
121. Gabriel CM, Gregson NA, Hughes RA. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol2000;104:139–46. 10.1016/S0165-5728(99)00269-6.
122. Ritz MF, Lechner-Scott J, Scott RJ, et al. . Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies. J Neuroimmunol2000;104:155–63. 10.1016/S0165-5728(99)00250-7.
123. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. . Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology2014;82:879–86. 10.1212/WNL.0000000000000205.
124. Ng JK, Malotka J, Kawakami N, et al. . Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology2012;79:2241–8. 10.1212/WNL.0b013e31827689ad.
125. Kawamura N, Yamasaki R, Yonekawa T, et al. . Anti-neurofascin antibody in patients with combined central and peripheral demyelination. Neurology2013;81:714–22. 10.1212/WNL.0b013e3182a1aa9c.
126. Devaux JJ, Odaka M, Yuki N. Nodal proteins are target antigens in Guillain-Barré syndrome. J PeripherNervSyst2012;17:62–71. 10.1111/j.1529-8027.2012.00372.x.
127. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. . Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. Ann Neurol2013;73:370–80. 10.1002/ana.23794.
128. Milner P, Lovelidge CA, Taylor WA, et al. . P0 myelin protein produces experimental allergic neuritis in Lewis rats. J NeurolSci1987;79:275–85. 10.1016/0022-510X(87)90235-8.
129. Kadlubowski M, Hughes RA. Identification of the neuritogen for experimental allergic neuritis. Nature1979;277:140–1. 10.1038/277140a0.
130. Gabriel CM, Hughes RA, Moore SE, et al. . Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain1998;121(Pt 10):1895–902. 10.1093/brain/121.10.1895.
131. Hughes RA, Powell HC, Braheny SL, et al. . Endoneurial injection of antisera to myelin antigens. Muscle Nerve1985;8:516–22. 10.1002/mus.880080607.
132. Devaux JJ. Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier. Am J Pathol2012;181:1402–13. 10.1016/j.ajpath.2012.06.034.
133. Amor V, Feinberg K, Eshed-Eisenbach Y, et al. . Long-term maintenance of Na+ channels at nodes of Ranvier depends on glial contact mediated by gliomedin and NrCAM. J Neurosci2014;34:5089–98. 10.1523/JNEUROSCI.4752-13.2014.
134. Salzer JL, Brophy PJ, Peles E. Molecular domains of myelinated axons in the peripheral nervous system. Glia2008;56:1532–40. 10.1002/glia.20750.
135. Thaxton C, Pillai AM, Pribisko AL, et al. . In vivo deletion of immunoglobulin domains 5 and 6 in neurofascin (Nfasc) reveals domain-specific requirements in myelinated axons. J Neurosci2010;30:4868–76. 10.1523/JNEUROSCI.5951-09.2010.
136. Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. ClinNeurophysiol2013;124:1928–34. 10.1016/j.clinph.2013.03.025.
137. Chavada G, Willison HJ. Autoantibodies in immune-mediated neuropathies. CurrOpinNeurol2012;25:550–5. 10.1097/WCO.0b013e328357a77f.
138. McGonigal R, Rowan EG, Greenshields KN, et al. . Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain2010;133:1944–60. 10.1093/brain/awq119.
139. Shahrizaila N, Kokubun N, Sawai S, et al. . Antibodies to single glycolipids and glycolipid complexes in Guillain-Barré syndrome subtypes. Neurology2014;83:118–24. 10.1212/WNL.0000000000000577.
140. Sawai S, Satoh M, Mori M, et al. . Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology2014;83:113–17. 10.1212/WNL.0000000000000566.
141. Notturno F, Di FT, Yuki N, et al. . Autoantibodies to neurofascin-186 and gliomedin in multifocal motor neuropathy. J Neuroimmunol2014;276:207–12. 10.1016/j.jneuroim.2014.09.001.
142. Cifuentes-Diaz C, Dubourg O, Irinopoulou T, et al. . Nodes of Ranvier and paranodes in chronic acquired neuropathies. PLoS ONE2011;6:e14533 10.1371/journal.pone.0014533.
143. Doppler K, Werner C, Sommer C. Disruption of nodal architecture in skin biopsies of patients with demyelinating neuropathies. J PeripherNervSyst2013;18:168–76. 10.1111/jns5.12023.
144. Lonigro A, Devaux JJ. Disruption of neurofascin and gliomedin at nodes of Ranvier precedes demyelination in experimental allergic neuritis. Brain2009;132:260–73. 10.1093/brain/awn281.
145. Yan W, Nguyen T, Yuki N, et al. . Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis. J Neuroimmunol2014;277:13–17. 10.1016/j.jneuroim.2014.09.012.
146. Davis JQ, Lambert S, Bennett V. Molecular composition of the node of Ranvier: identification of ankyrin-binding cell adhesion molecules neurofascin (mucin+/third FNIII domain-) and NrCAM at nodal axon segments. J Cell Biol1996;135:1355–67. 10.1083/jcb.135.5.1355.
147. Mathey EK, Derfuss T, Storch MK, et al. . Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med2007;204:2363–72. 10.1084/jem.20071053.
148. Nirula A, Glaser SM, Kalled SL, et al. . What is IgG4? A review of the biology of a unique immunoglobulin subtype. CurrOpinRheumatol2011;23: 119–24. 10.1097/BOR.0b013e3283412fd4.
149. Huijbers MG, Zhang W, Klooster R, et al. . MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. ProcNatlAcadSci USA2013;110:20783–8. 10.1073/pnas.1313944110.
150. Labasque M, Hivert B, Nogales-Gadea G, et al. . Specific Contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies. J BiolChem2014;289:7907–18. 10.1074/jbc.M113.528489.
151. Lindner M, Ng JK, Hochmeister S, et al. . Neurofascin 186 specific autoantibodies induce axonal injury and exacerbate disease severity in experimental autoimmune encephalomyelitis. ExpNeurol2013;247C:259–66. 10.1016/j.expneurol.2013.05.005.
152. Charles P, Tait S, Faivre-Sarrailh C, et al. . Neurofascin is a glial receptor for the paranodin/Caspr-contactin axonal complex at the axoglial junction. CurrBiol2002;12:217–20. 10.1016/S0960-9822(01)00680-7.
153. Rinaldi S, Brennan KM, Kalna G, et al. . Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome. PLoS ONE2013;8:e82337 10.1371/journal.pone.0082337.
154. Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol2013;34:453–9. 10.1016/j.it.2013.05.001.
155. Cappelen-Smith C, Kuwabara S, Lin CS, et al. . Membrane properties in chronic inflammatory demyelinating polyneuropathy. Brain2001;124:2439–47. 10.1093/brain/124.12.2439.
156. Lin CS, Krishnan AV, Park SB, et al. . Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch Neurol2011;68:862–9. 10.1001/archneurol.2011.137.
157. Dalakas MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol2011;7:507–17. 10.1038/nrneurol.2011.121.
158. Tasaki I. Conduction of the nerve impulse. In: Field J, Magoun HW, Hall VE. Handbook of physiology, Section 1, neurophysiology. Washington DC: American Physiological Society, 1959:75–121.
159. Bostock H, Grafe P. Activity-dependent excitability changes in normal and demyelinated rat spinal root axons. J Physiol1985;365:239–57. 10.1113/jphysiol.1985.sp015769.
160. Cappelen-Smith C, Kuwabara S, Lin CS, et al. . Activity-dependent hyperpolarization and conduction block in chronic inflammatory demyelinating polyneuropathy. Ann Neurol2000;48:826–32. 10.1002/1531-8249(200012)48:6<826::AID-ANA2>3.0.CO;2-P.
161. Hitomi T, Kaji R, Murase N, et al. . Dynamic change of proximal conduction in demyelinating neuropathies: a cervical magnetic stimulation combined with maximum voluntary contraction. ClinNeurophysiol2007;118:741–50. 10.1016/j.clinph.2006.11.013.
162. Straver DC, van den Berg LH, Franssen H. Activity-dependent conduction block in chronic inflammatory demyelinating polyneuropathy. J NeurolSci2011;300:33–8. 10.1016/j.jns.2010.10.008.
163. Kiernan MC, Lin CS, Burke D. Differences in activity-dependent hyperpolarization in human sensory and motor axons. J Physiol2004;558:341–9. 10.1113/jphysiol.2004.063966.
164. Howells J, Trevillion L, Bostock H, et al. . The voltage dependence of I(h) in human myelinated axons. J Physiol2012;590:1625–40. 10.1113/jphysiol.2011.225573.
165. Eftimov F, Liesdek MH, Verhamme C, et al. . Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern. BMC Neurol2014;14:72 10.1186/1471-2377-14-72.
166. Hall ED, Baker T, Riker WF Jr. Glucocorticoid effects on spinal cord function. J PharmacolExpTher1978;206:361–70.
167. Braughler JM, Hall ED. Acute enhancement of spinal cord synaptosomal (Na+ + K+)-ATPase activity in cats following intravenous methylprednisolone. Brain Res1981;219:464–9. 10.1016/0006-8993(81)90311-5.
168. Hall ED. Glucocorticoid effects on the electrical properties of spinal motor neurons. Brain Res1982;240:109–16. 10.1016/0006-8993(82)90648-5.
169. Nordsborg N, Thomassen M, Lundby C, et al. . Contraction-induced increases in Na+-K+-ATPase mRNA levels in human skeletal muscle are not amplified by activation of additional muscle mass. Am J PhysiolRegulIntegr Comp Physiol2005;289:R84–91. 10.1152/ajpregu.00771.2004.